Optimizing secondary prevention of cervical cancer: Recent advances and future challenges

International Journal of Gynecology and Obstetrics

Volumn 138, Issue , 2017, Pages 15-19

  Ogilvie, Gina ^a,b   Nakisige, Carolyn ^c   Huh, Warner K ^d   Mehrotra, Ravi ^e   Franco, Eduardo L ^f   Jeronimo, Jose ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^c UGANDA CANCER INSTITUTE   (Uganda)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e ICMR NATIONAL INSTITUTE OF CANCER PREVENTION AND RESEARCH   (India)

^f MCGILL UNIVERSITY   (Canada)

^g PATH   (United States)

Author keywords

Cervical cancer; Eradication; HPV; Screening; Self collection

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; CLINICAL PROTOCOL; COMMUNITY; EDUCATION; FEMALE; FUTUROLOGY; HEALTH CARE PLANNING; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MEDICAL INFORMATION SYSTEM; META ANALYSIS (TOPIC); PRIORITY JOURNAL; QUALITY CONTROL; SECONDARY PREVENTION; UTERINE CERVIX CANCER; EARLY CANCER DIAGNOSIS; GLOBAL HEALTH; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; WOMEN'S HEALTH;

EARLY DETECTION OF CANCER; FEMALE; GLOBAL HEALTH; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SECONDARY PREVENTION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; WOMEN'S HEALTH;

EID: 85022084708     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1002/ijgo.12187     Document Type: Article

References (34)

1. Bosch FX, Robles C, Diaz M, et al. HPV-FASTER: Broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13:119–132.
2. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. Lancet Glob Health. 2016;4:e453–e463.
3. World Health Organization. Human Papillomavirus (HPV) Vaccine Background Paper. Geneva: WHO; 2008.
4. Ginsburg O, Bray F, Coleman MP, et al. The global burden of women's cancers: A grand challenge in global health. Lancet. 2017;389:847–860.
5. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med. 1997;121:211–224.
6. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–1101.
7. Sankaranarayanan R, Thara S, Sharma A, et al. Accuracy of conventional cytology: Results from a multicentre screening study in India. J Med Screen. 2004;11:77–84.
8. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed December 8, 2016.
9. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19.
10. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet. 2014;383:524–532.
11. Gage JC, Katki HA, Schiffman M, et al. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathol. 2014;122:842–850.
12. World Health Organization. Comprehensive Cervical Cancer Control: A Guide to Essential Practice, 2nd edn. Geneva: WHO; 2014.
13. Jeronimo J, Castle PE, Temin S, et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Glob Oncol. 2016:JGO006577.
14. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecol Oncol. 2015;136:178–182.
15. Tota JE, Bentley J, Blake J, et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Prev Med. 2017;98:5–14.
16. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: Systematic review and meta-analysis. BMJ. 2014;349:g6192.
17. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: Low average levels and large inequalities. PLoS Med. 2008;5:e132.
18. Driscoll SD. Barriers and facilitators to cervical cancer screening in high incidence populations: A synthesis of qualitative evidence. Women Health. 2016;56:448–467.
19. Lim JN, Ojo AA. Barriers to utilisation of cervical cancer screening in Sub Sahara Africa: A systematic review. Eur J Cancer Care (Engl). 2017;26(1).
20. Qiao YL, Jeronimo J, Zhao FH, et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer. 2014;134:2891–2901.
21. Arbyn M, Verdoodt F, Snijders PJF, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: A meta-analysis. Lancet Oncol. 2014;15:172–183.
22. Racey CS, Withrow DR, Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: A systematic review and meta-analysis. Can J Public Health. 2013;104:e159–e166.
23. Moses E, Pedersen H, Mitchell S, et al. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: Preliminary results of a randomised controlled trial. Tropical Med Int Health. 2015;20:1355–1367.
24. Arbyn M, Castle PE. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev. 2015;24:769–772.
25. Jeronimo J, Holme F, Slavkovsky R, Camel C. Implementation of HPV testing in Latin America. J Clin Virol. 2016;76:S69–S73.
26. Arrossi S, Thouyaret L, Laudi R, et al. Implementation of HPV-testing for cervical cancer screening in programmatic contexts: The Jujuy demonstration project in Argentina. Int J Cancer. 2015;137:1709–1718.
27. Jeronimo J, Holme F, Camel C, Maldonado F. Screening hard-to-reach women in population-based programs using self-sampling: experiences from Nicaragua and Guatemala. Abstract presented at HPV 2017, 2017, Cape Town, South Africa.
28. Coldman AJ, Phillips N, van Niekerk D, et al. Projected impact of HPV and LBC primary testing on rates of referral for colposcopy in a Canadian cervical cancer screening program. J Obstet Gynaecol Can. 2015;37:412–420.
29. Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M. The HPV test has similar sensitivity but more overdiagnosis than the Pap test–a randomised health services study on cervical cancer screening in Finland. Int J Cancer. 2013;132:2141–2147.
30. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14:395–405.
31. Ogilvie GS, Smith LW, van Niekerk DJ, et al. Women's intentions to receive cervical cancer screening with primary human papillomavirus testing. Int J Cancer. 2013;133:2934–2943.
32. Regier DA, van der Hoek K, Ogilvie G, et al. Exploring colposcopists’ attitudes towards use of HPV testing as a primary screening tool for cervical cancer in British Columbia. J Obstet Gynaecol Can. 2013;35:657–663.
33. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlée F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: The need for a paradigm change. Arch Med Res. 2009;40:478–485.
34. El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J Clin Virol. 2016;76(Suppl.1):S62–S68.